Related Experiment Video
Updated: Aug 20, 2026

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials
Published on: May 31, 2024
Botulinum toxin type A in the management of masseter muscle hypertrophy
Wagner Henriques Castro1, Rodrigo Santiago Gomez, Jacqueline Da Silva Oliveira
1Department of Oral Surgery and Oral Pathology, School of Dentistry, University of Minas Gerais, Belo Horizonte, Brazil. wagnercastro@ufmg.br
Purpose:
We sought to evaluate the response of 6 patients with masseter muscle hypertrophy to botulinum toxin type A therapy.
Patients And Methods:
Six patients with unilateral or bilateral masseter muscle hypertrophy received intramuscular injection of the botulinum toxin type A. The functional and cosmetic results were evaluated as well as recurrence.
Results:
In all patients, satisfactory regression of the masseter muscle hypertrophy occurred and mild muscular pain was relieved. Recurrence was observed in 2 cases.
Conclusions:
The use of botulinum toxin type A in masseter muscle hypertrophy therapy was shown to be a successful and safe treatment method. This procedure to control parafunctional activities involving the masticatory muscles of patients appears to be useful.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Tetanus
